104 related articles for article (PubMed ID: 11245212)
21. Specific substrate for CLN2 protease/tripeptidyl-peptidase I assay.
Junaid MA; Brooks SS; Pullarkat RK
Eur J Paediatr Neurol; 2001; 5 Suppl A():63-8. PubMed ID: 11589010
[TBL] [Abstract][Full Text] [Related]
22. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
Kohlschütter A; Schulz A
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
[TBL] [Abstract][Full Text] [Related]
23. The specificity of lysosomal tripeptidyl peptidase-I determined by its action on angiotensin-II analogues.
Warburton MJ; Bernardini F
FEBS Lett; 2001 Jul; 500(3):145-8. PubMed ID: 11445074
[TBL] [Abstract][Full Text] [Related]
24. Maturation of human tripeptidyl-peptidase I in vitro.
Golabek AA; Wujek P; Walus M; Bieler S; Soto C; Wisniewski KE; Kida E
J Biol Chem; 2004 Jul; 279(30):31058-67. PubMed ID: 15143070
[TBL] [Abstract][Full Text] [Related]
25. Developmental study of tripeptidyl peptidase I activity in the mouse central nervous system and peripheral organs.
Dimitrova M; Deleva D; Pavlova V; Ivanov I
Cell Tissue Res; 2011 Nov; 346(2):141-9. PubMed ID: 21996941
[TBL] [Abstract][Full Text] [Related]
26. Palmitoyl Protein Thioesterase1 (PPT1) and Tripeptidyl Peptidase-I (TPP-I) are expressed in the human saliva. A reliable and non-invasive source for the diagnosis of infantile (CLN1) and late infantile (CLN2) neuronal ceroid lipofuscinoses.
Kohan R; Noher de Halac I; Tapia Anzolini V; Cismondi A; Oller Ramírez AM; Paschini Capra A; de Kremer RD
Clin Biochem; 2005 May; 38(5):492-4. PubMed ID: 15820783
[No Abstract] [Full Text] [Related]
27. Detection of tripeptidyl peptidase I activity in living cells by fluorogenic substrates.
Steinfeld R; Fuhrmann JC; Gärtner J
J Histochem Cytochem; 2006 Sep; 54(9):991-6. PubMed ID: 16782851
[TBL] [Abstract][Full Text] [Related]
28. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
Chang M; Cooper JD; Sleat DE; Cheng SH; Dodge JC; Passini MA; Lobel P; Davidson BL
Mol Ther; 2008 Apr; 16(4):649-56. PubMed ID: 18362923
[TBL] [Abstract][Full Text] [Related]
29. N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I.
Wujek P; Kida E; Walus M; Wisniewski KE; Golabek AA
J Biol Chem; 2004 Mar; 279(13):12827-39. PubMed ID: 14702339
[TBL] [Abstract][Full Text] [Related]
30. Analysis of catalytic properties of tripeptidyl peptidase I (TTP-I), a serine carboxyl lysosomal protease, and its detection in tissue extracts using selective FRET peptide substrate.
Kondo MY; Gouvea IE; Okamoto DN; Santos JA; Souccar C; Oda K; Juliano L; Juliano MA
Peptides; 2016 Feb; 76():80-6. PubMed ID: 26775801
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
[TBL] [Abstract][Full Text] [Related]
32. Prosegment of tripeptidyl peptidase I is a potent, slow-binding inhibitor of its cognate enzyme.
Golabek AA; Dolzhanskaya N; Walus M; Wisniewski KE; Kida E
J Biol Chem; 2008 Jun; 283(24):16497-504. PubMed ID: 18411270
[TBL] [Abstract][Full Text] [Related]
33. The expression of late infantile neuronal ceroid lipofuscinosis (CLN2) gene product in human brains.
Oka A; Kurachi Y; Mizuguchi M; Hayashi M; Takashima S
Neurosci Lett; 1998 Nov; 257(2):113-5. PubMed ID: 9865940
[TBL] [Abstract][Full Text] [Related]
34. R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis.
Barisić N; Logan P; Pikija S; Skarpa D; Blau N
Croat Med J; 2003 Aug; 44(4):489-93. PubMed ID: 12950156
[TBL] [Abstract][Full Text] [Related]
35. Histochemical demonstration of tripeptidyl aminopeptidase I in the rat carotid body.
Atanasova D; Lazarov N
Acta Histochem; 2015 Mar; 117(2):219-22. PubMed ID: 25636608
[TBL] [Abstract][Full Text] [Related]
36. Expression and analysis of CLN2 variants in CHO cells: Q100R represents a polymorphism, and G389E and R447H represent loss-of-function mutations.
Lin L; Lobel P
Hum Mutat; 2001 Aug; 18(2):165. PubMed ID: 11462245
[TBL] [Abstract][Full Text] [Related]
37. Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates.
Tian Y; Sohar I; Taylor JW; Lobel P
J Biol Chem; 2006 Mar; 281(10):6559-72. PubMed ID: 16339154
[TBL] [Abstract][Full Text] [Related]
38. Ser475, Glu272, Asp276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I.
Walus M; Kida E; Wisniewski KE; Golabek AA
FEBS Lett; 2005 Feb; 579(6):1383-8. PubMed ID: 15733845
[TBL] [Abstract][Full Text] [Related]
39. Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.
Goldberg-Stern H; Halevi A; Marom D; Straussberg R; Mimouni-Bloch A
Pediatr Neurol; 2009 Oct; 41(4):297-300. PubMed ID: 19748052
[TBL] [Abstract][Full Text] [Related]
40. The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH.
Lin L; Sohar I; Lackland H; Lobel P
J Biol Chem; 2001 Jan; 276(3):2249-55. PubMed ID: 11054422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
